Thank you. Good morning, everyone, and thank you for joining our second quarter conference call. Before we discuss the operational and financial highlights for the quarter, we would first like to discuss an important matter.After an extensive and further review of our first quarter financials, we determined that the purchase accounting relating to the acquisition of Certain Assets of Kilitch Drugs, that were acquired earlier this year, was incorrect, and required another set of review. We plan to reflect the corrected accounting in the amended 10-Q for the first quarter shortly. As a result, we are reporting preliminary results for the second quarter, and have preliminarily restated the earlier results with the estimated impact of the corrected purchase accounting. The final numbers will be reflected in the 10-Q to be filed later. We sincerely apologize for the error. However, the good news is that it does not affect our ongoing sales and ongoing operating results. I will let Tim discuss this in detail, and we’ll come back on the call to discuss the second quarter highlights. Tim?
Akorn CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.